Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Blair Childs to GPO: AdvaMed's former VP-strategic planning Blair Childs is appointed senior VP-public affairs at the Premier hospital group purchasing organization July 25. Childs will lead Premier's lobbying efforts in Washington, D.C., and will act as the organization's primary spokesperson, according to the company. GPOs are under pressure from Congress, where members are considering various legislative options for strengthening oversight of the groups (1"The Gray Sheet" March 20, 2006, p. 16). The Medical Device Manufacturers Association has been particularly active in pushing for tighter GPO regulations out of concerns that the groups have conflicted financial interests that can lock smaller manufacturers out of hospital contracts...

You may also be interested in...

GPO Legislation On Hold; Senate Waits On Further Stakeholder Comment

The Senate Judiciary/Antitrust Subcommittee is awaiting further feedback from stakeholders before moving forward with legislation to regulate group purchasing organization practices, following an inconclusive March 15 hearing

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts